Progestins have become normal medical practice in the treatment of endometrial carcinoma. An accurate review of the literature on the subject, involving about 1500 treated cases since 1951, reveals that a positive response is obtained in about 30% of cases. However, authors differ greatly as to the kind of progestin to be administered, and especially as to the dosage, which can go from 0.2 to 5.6 gr. According to the authors of this article great importance must be given to plasmatic levels and to the analysis of hormonal receptors before deciding on the type of therapy. Results from their personal observations of 45 cases show that some patients would benefit more from progestin thersapy, and others from traditional chemothersapy.
Nicholas L. Smith, Susan R. Heckbert, Rozenn N. Lemaître, Alex P. Reiner, Thomas Lumley, Noel S. Weiss, Eric B. Larson, Frits R. Rosendaal, Bruce M. Psaty
Mary Cushman, Joseph C. Larson, Frits R. Rosendaal, Lawrence S. Phillips, Barbara V. Howard, J. David Curb, Jennifer Hays, Alison E. Baird, Charles B. Eaton, Susan R. Heckbert, Randall S. Stafford
Discussion(0)
No comments yet. Be the first to comment.